Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1992 2
1993 5
1994 4
1995 3
1996 3
1997 1
2000 1
2001 2
2002 2
2003 2
2004 1
2005 1
2007 3
2008 3
2009 2
2010 2
2011 3
2012 2
2013 4
2014 2
2016 2
2017 3
2018 4
2019 2
2020 3
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

59 results
Results by year
Filters applied: . Clear all
Page 1
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. DiNardo CD, et al. Among authors: thirman mj. N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971. N Engl J Med. 2020. PMID: 32786187 Clinical Trial.
Treatment of Acute Promyelocytic Leukemia in Adults.
Osman AEG, Anderson J, Churpek JE, Christ TN, Curran E, Godley LA, Liu H, Thirman MJ, Odenike T, Stock W, Larson RA. Osman AEG, et al. Among authors: thirman mj. J Oncol Pract. 2018 Nov;14(11):649-657. doi: 10.1200/JOP.18.00328. J Oncol Pract. 2018. PMID: 30423270 Review.
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, Konopleva M, Thirman MJ, Arellano M, Becker PS, Chyla B, Hong WJ, Jiang Q, Potluri J, DiNardo CD. Pollyea DA, et al. Among authors: thirman mj. Am J Hematol. 2021 Feb 1;96(2):208-217. doi: 10.1002/ajh.26039. Epub 2020 Nov 10. Am J Hematol. 2021. PMID: 33119898 Clinical Trial.
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. O'Brien S, et al. Among authors: thirman mj. Lancet Oncol. 2016 Oct;17(10):1409-1418. doi: 10.1016/S1470-2045(16)30212-1. Epub 2016 Sep 13. Lancet Oncol. 2016. PMID: 27637985 Clinical Trial.
Therapy-related myeloid leukemia.
Thirman MJ, Larson RA. Thirman MJ, et al. Hematol Oncol Clin North Am. 1996 Apr;10(2):293-320. doi: 10.1016/s0889-8588(05)70340-3. Hematol Oncol Clin North Am. 1996. PMID: 8707757 Review.
Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis.
Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo WL, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw KL, Bhattacharyya S, Bishop MR, Artz A, Thirman MJ, Moliterno A, Ji P, Levine RL, Godley LA, Steidl U, Bieker JJ, List AF, Saunthararajah Y, He C, Verma A, Wickrema A. Jeong JJ, et al. Among authors: thirman mj. Cancer Discov. 2019 Jun;9(6):778-795. doi: 10.1158/2159-8290.CD-18-1138. Epub 2019 Apr 3. Cancer Discov. 2019. PMID: 30944118 Free PMC article.
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.
Cahill KE, Karimi YH, Karrison TG, Jain N, Green M, Weiner H, Fulton N, Kadri S, Godley LA, Artz AS, Liu H, Thirman MJ, Le Beau MM, McNerney ME, Segal J, Larson RA, Stock W, Odenike O. Cahill KE, et al. Among authors: thirman mj. Blood Adv. 2020 Feb 25;4(4):599-606. doi: 10.1182/bloodadvances.2019000795. Blood Adv. 2020. PMID: 32074275 Free PMC article. Clinical Trial.
59 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page